Soleno Therapeutics(SLNO)
REDWOOD CITY, CABiotechnology
Focus: Soleno is a public-stage biotech focused on metabolic diseases, with a commercialized small molecule (VYKAT XR) and a pipeline concentrated on rare genetic obesity disorders. The company is headquartered in Redwood City, CA and operates at mid-cap biotech scale with $190M revenue in FY2025.
Profile data last refreshed 13h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Total Funding
$NaNB
Open Jobs
6+6 this month
Growing — net +6 jobs in 30d
6 jobs added vs 0 removed. Steady team buildout.
Should You Work at Soleno Therapeutics?
AI assessmentEarly-stage commercial biotech with validated revenue but deteriorating unit economics and zero hiring activity—suitable for risk-tolerant professionals seeking upside in rare metabolic diseases, but with near-term execution uncertainty.
Why Work Here
- Commercial growth opportunity: $190M revenue in FY2025 with VYKAT XR in growth phase (LOE 2035) provides 10+ years of runway
Data completeness
7/9 — Strong
Company HealthStrong
Pipeline
Late-stage
4 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$190M
Key Products
Growth9.4yr
Only marketed product; NDA approved with 10+ year exclusivity, providing commercial foundation and clinical validation for pipeline expansion into related obesity indications.
Help build intelligence for Soleno Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.